Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human/Mouse/Rat |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit monoclonal antibody anti-Olig1 (172-271) is suitable for use in Western Blot research applications. |
Clonality: |
Monoclonal |
Clone ID: |
S4MR |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.02% Sodium Azide, 0.05% BSA, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:1000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
OLIG1 |
Gene ID: |
116448 |
Uniprot ID: |
OLIG1_HUMAN |
Immunogen Region: |
172-271 |
Immunogen: |
A synthetic peptide corresponding to a sequence within amino acids 172-271 of human Olig1 (Q8TAK6). |
Immunogen Sequence: |
RRALGEGAGPAAPRLLLAGL PLLAAAPGSVLLAPGAVGPP DALRPAKYLSLALDEPPCGQ FALPGGGAGGPGLCTCAVCK FPHLVPASLGLAAVQAQFSK |
Tissue Specificity | Expressed in the brain, in oligodendrocytes. Strongly expressed in oligodendrogliomas, while expression is weak to moderate in astrocytomas. Expression in glioblastomas is highly variable. |
Function | Promotes formation and maturation of oligodendrocytes, especially within the brain. Cooperates with OLIG2 to establish the pMN domain of the embryonic neural tube. |
Protein Name | Oligodendrocyte Transcription Factor 1Oligo1Class B Basic Helix-Loop-Helix Protein 6Bhlhb6Class E Basic Helix-Loop-Helix Protein 21Bhlhe21 |
Cellular Localisation | Nucleus |
Alternative Antibody Names | Anti-Oligodendrocyte Transcription Factor 1 antibodyAnti-Oligo1 antibodyAnti-Class B Basic Helix-Loop-Helix Protein 6 antibodyAnti-Bhlhb6 antibodyAnti-Class E Basic Helix-Loop-Helix Protein 21 antibodyAnti-Bhlhe21 antibodyAnti-OLIG1 antibodyAnti-BHLHB6 antibodyAnti-BHLHE21 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance